363-40-6

Usage

Uses

Used in Pharmaceutical Industry:
2',4',6'-Trifluoroacetanilide is used as a reagent for the synthesis of various pharmaceutical compounds. Its unique properties and reactivity make it a valuable component in the development of new drugs and medicinal agents.
Used in Agrochemical Industry:
In the agrochemical sector, 2',4',6'-Trifluoroacetanilide is utilized as a reagent in the synthesis of compounds that have applications in crop protection and pest control, contributing to the development of more effective and targeted agrochemicals.
Used in Research and Development:
2',4',6'-Trifluoroacetanilide serves as an intermediate in the production of organic compounds, facilitating the exploration of new chemical reactions and the creation of novel organic molecules for various applications in research and development processes.

InChI:InChI=1/C8H6F3NO/c1-4(13)12-8-6(10)2-5(9)3-7(8)11/h2-3H,1H3,(H,12,13)

Upstream product

• 363-81-5 2,4,6-trifluoroaniline 
• 108-24-7 acetic anhydride 

Downstream Products

• 123797-03-5 C₆H₃F₃N₂ 
• 123825-40-1 C₆HF₃N₂ 
• 123797-02-4 2,4,6-trifluoro-1,3-diazobenzene 
• 123797-07-9 2,4,6-trifluoro-1,3-phenylenediamine 
• 153937-30-5 2-Amino-3,5-difluoro-benzenethiol 

Relevant academic research and scientific papers

Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC50 of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED50's of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t1/2, 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (Cmax in sciatic nerve and eye are 2.36 and 1.45 μg equiv/g, respectively, when dosed with [14C] lidorestat at 10 mg/kg po).

EPR SPECTROSCOPY OF A DIAZA DERIVATIVE OF META-XYLYLENE

Photolysis of 2,4,6-trifluoro-1,3-diazidobenzene in 2-methyltetrahydrofuran at 77k produces a dinitrene quintet.Upon warming the quintet briefly to 100K followed by recooling to 77K the EPR spectrum of the quintet disappears and is replaced by that of a trifluorodiaza biradical.